– CANADA, Hamilton – Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company today announced the appointments of Dr. Jeremy Bender (Ph.D.), Teresa Bitetti, and David Meek to its Board of Directors, effective immediately, succeeding Dr. Johan Christenson, Chau Khuong and Dr. Heather Preston who stepped down from the Board immediately.
“We are excited to welcome Jeremy, Teresa and David to Fusion’s Board of Directors, each bringing an exceptional breadth of experience and track record of success in oncology drug development, business development and commercialization. Their experiences introducing innovative therapies to cancer patients as leaders of top-tier oncology companies will be invaluable as we advance our pipeline, particularly our lead program FPI-2265, which is on track to be the first actinium-based PSMA targeted alpha therapy to market,” said CEO, Dr. John Valliant.
“I want to thank Johan, Chau, and Heather for their significant contributions and unwavering support that enabled Fusion to become a vertically integrated radiopharmaceutical company with a deep clinical-stage pipeline and a proprietary radiopharmaceutical manufacturing facility,” Dr. Valliant said.
About Dr. Jeremy Bender
Dr. Jeremy Bender is currently CEO of Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on pediatric cancer. Previously, Dr. Bender served as VP of Corporate Development at Gilead Sciences, overseeing acquisitions, partnerships, and investments. He also served as COO at Tizona Therapeutics, CBO at Sutro Biopharma, and VP of Corporate Development at Allos Therapeutics, and began his career at Boston Consulting Group in the life sciences practice. He currently sits on the Board of Mereo BioPharma as an Independent Board Member.
Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.
About Teresa Bitetti
Ms. Teresa Bitetti currently serves as President of the Global Oncology Business Unit of Takeda. Previously, Ms. Bitetti held various roles of increasing responsibility at Bristol-Myers Squibb Company, including as SVP, and Head of Worldwide Oncology Commercialization. At BMS, she also served as SVP and Head of the U.S. Oncology business, President and General Manager of BMS Canada, and Worldwide Head of the BMS Virology business. Before BMS, Ms. Bitetti also held various roles of increasing responsibility at Mobil Oil Corporation. Ms. Bitetti currently serves on the board of Osmol Therapeutics as an independent director.
Ms. Bitetti holds a B.A. from Wellesley College and an M.B.A. from the Darden School of Business at the University of Virginia.
About David Meek
Mr. David Meek most recently served as CEO and Member of the Board of Directors of Mirati Therapeutics. Before this role, he served as the President, CEO, and Board Member of FerGene and CEO and Board Member of Ipsen. Mr. Meek was previously an EVP and President of Oncology at Baxalta Incorporated in the leadup to the acquisition by Shire and CCO of Endocyte, and he held executive leadership roles at Novartis Pharmaceuticals Corporation and Novartis Oncology. Mr. Meek has served on the boards of Pharmaceutical Research & Manufacturers of America and the European Federation of Pharmaceutical Industries & Associations. He currently serves on the Board of Directors of uniQure N.V. and previously served on the Board of Directors of Entasis Therapeutics (acquired by Innoviva).
Mr. Meek holds a B.A. from the University of Cincinnati.
About Fusion Pharmaceuticals
Fusion is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle-emitting isotopes to various targeting molecules to selectively deliver the alpha-emitting payloads to tumors. Fusion’s clinical portfolio includes FPI-2265 targeting prostate-specific membrane antigen for metastatic castration-resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial; and FPI-2059, a small molecule targeting neurotensin receptor 1, currently in a Phase 1 trial. In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies and combination programs between Fusion’s TATs and AstraZeneca’s DNA Damage Response Inhibitors and immuno-oncology agents.
SOURCE: https://fusionpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
